Morepen Laboratories reached a major milestone, securing multi-year CDMO mandate valued at approx. ₹825 crore. This significant agreement involves supplies commencing within 4-5 months. Leveraging four decades of API expertise and USFDA approvals, Morepen is scaling its global manufacturing footprint to meet increasing demand for compliant, scalable manufacturing platforms in regulated markets.